Roche of Switzerland, best known for its valium sedative, is preparing a fresh offer for Genentech, the US biotechnology company in which it owns a stake of 56 per cent.
The bid, expected to be pitched at about $95 a share, is likely to be presented to Genentech's board ahead of Roche's year-end figures, due in early February.
